See the DrugPatentWatch profile for januvia
Core Januvia Patents and Expiry Dates
Januvia (sitagliptin), made by Merck, has multiple patents listed in the FDA's Orange Book. The primary composition-of-matter patent (U.S. Patent No. 6,699,871) expired on February 17, 2027, after pediatric exclusivity extension.[1][2] This covers the active ingredient itself.
When Do Other Key Patents Expire?
- Formulation patents: U.S. Patent No. 7,326,708 (for the phosphate salt form used in Januvia) expires March 21, 2026.[1][2]
- Method-of-use patents: Several extend to 2030 or later, including No. 8,414,921 (expires September 2031) for treating type 2 diabetes.[2]
- Combination product patents (e.g., Janumet with metformin): Vary, with some expiring in 2026–2033.[1]
Generic entry often hinges on the earliest expiry plus any litigation outcomes, potentially allowing competition by late 2026 despite later patents.
What Litigation Delays Generic Entry?
Merck has defended Januvia patents through ANDA lawsuits. In 2019, a Delaware court invalidated some secondary patents but upheld others, pushing back generic approvals. Ongoing Paragraph IV challenges from Mylan, Viatris, and others could lead to earlier entry if patents are overturned, but Merck won key rulings in 2022–2023.[1][3]
Generic Availability Timeline
No generics are approved yet. The first wave likely launches post-March 2026 (formulation expiry), assuming no further extensions or losses in court. FDA tentative approvals exist for several ANDAs, signaling readiness.[2] Patient assistance programs from Merck bridge the gap until then.
How Does Sitagliptin Compare to Other DPP-4 Inhibitors?
Januvia faces competition from generics of Onglyza (saxagliptin, patent expired 2023) and Tradjenta (linagliptin, generics expected 2025).[1] These alternatives are cheaper post-patent, with similar efficacy for blood sugar control but varying side effect profiles (e.g., Onglyza's heart failure warnings).
Pricing and Cost After Patent Cliff
U.S. list price for 100mg Januvia is about $600/month. Post-expiry, generics could drop costs 80–90%, mirroring trends with other blockbusters.[3]
Sources:
[1]: DrugPatentWatch.com - Januvia Patents
[2]: FDA Orange Book - Sitagliptin Patents
[3]: FDA Generic Approvals Tracker